Health

DongKoo Bio & Pharma’s biotech investments are showing progress across commercialization, clinical development and IPO preparations, with Quriant partnering with Lonza on an antibody-drug conjugate platform, D&D Pharmatech reporting Phase 2 results for a liver disease drug candidate, and Novacell Technology pursuing a Kosdaq listing.

Yipseel has received a decision to grant a South Korean patent for its low-immunogenicity universal induced pluripotent stem cell technology and plans to expand cell therapy development and clinical-grade cell line supply.

G2G Bio plans to introduce its InnoBioLAMP platform for ultra-high-concentration antibody formulations at PODD 2026, aiming to make subcutaneous administration more convenient and expand partnerships with global pharmaceutical companies.

VAIM launched its Juvelook skincare products in China, expanding its market presence after receiving medical device approval.

Wontech secures CE MDR certification for three core products, aiming to expand into the European market and boost overseas growth.

AITRICS has been named one of the world's top health tech companies by TIME and Statista, receiving an Outstanding rating in AI and data analysis.

Celltrion completes negotiations with a major U.S. PBM for high-revenue products, aiming for additional contracts in Q4.

Neurophet recognized for medical innovation and AI-driven clinical development at Asia Bio Industry Awards.

GC Medical Science signed an MOU with Jiangsu Yuwell Medical Equipment Co. for strategic partnership on October 12.

Daewoong Pharmaceutical is building facilities for microneedle drugs and accelerating commercialization of obesity and diabetes patches.

Qurient announced its dual payload antibody-drug conjugate platform strategy developed with global partner Lonza at the 17th World ADC 2026.

Yuyu Pharma showcased its pet health supplements at a cat expo in the U.S., targeting the North American market.

Korea's ARPA-H is developing long-lasting vaccines and treatment technologies to eliminate latent pathogens through competitive research.

IVIM Technology discussed collaborations in bi imaging-based CRO services at a Japan exhibition, securing new business opportunities.